Pharmaceutical Research Associates, Inc.,
Lenexa, Kansas, 66219, United States
NCT Number: NCT03187496
A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human volunteers.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Lenexa, Kansas, 66219, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each subject will receive midazolam on Days 1 and 12.
Each subject will receive caffeine on Days 1 and 12.
Each subject will receive rosuvastatin on Days 2 and 13.
Each subject will receive EDP-305 on Days 5 through 15.
Time frame: Up to 17 Days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Time frame: Up to 17 days
Enanta Pharmaceuticals, Inc
Industry
A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-305 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Human Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05935488
Digestive System Diseases, Fibrosis
Norwich, Norfolk, United Kingdom
View Trial DetailsNCT05327127
NASH
Tucson, Arizona, United States
View Trial DetailsNCT06697977
Body Weight, Diabetes
Amman, Jordan
View Trial DetailsNCT06410924
Digestive System Diseases, Fatty Liver
Maitland, Florida, United States
View Trial Details